|
Aurélien Olichon obtained his PhD in March 2004 at the University of Toulouse. He worked on the intramitochondrial dynamin, OPA1, linked with type I Dominant Optic Atrophy . Then, in 2004, Aurélien joined Thomas Surrey's laboratory at EMBL in Heidelberg as a post-doctoral fellow. He implemented the selection of camelid antibody fragments (VHH) by phage display. He was able to develop nanobodies targeting several antigens, including microtubules, mitotic spindle-associated proteins, and antibodies blocking rotavirus infection. Since September 2008, he has been an assistant professor in biochemistry and molecular biology at the Faculty of Pharmaceutical Sciences of the University of Toulouse. In Prof. Gille Favre's laboratory at the Claudius Regaud Institute and then at the Cancer Research Center of Toulouse (CRCT), Aurélien designed a fully synthetic nanobody library and developed his expertise in recombinant antibody technology. Of note, he generated several highly selective nanobodies for the active conformations of RHO GTPases for immunometric assays, intracellular biosensors, and targeted protein degradation. In September 2020, Aurélien moved to the University of La Reunion as an associate professor in pharmacology. He joined the DéTROI laboratory, where he works on engineering nanobody-based biosensors or inhibitors targeting biomarkers of chronic diseases.
|
Scientific summary
Engineering nanobody-based biosensors targeting biomarkers of cardiovascular and inflammatory diseases.
Selected PUBLICATIONS
Visualizing the subcellular localization of RHOB-GTP and GTPase-Effector complexes using a split-GFP/nanobody labelling assay.
Castillo S, Gence R, Pagan D, Koraïchi F, Bouchenot C, Pons BJ, Boëlle B, Olichon A, Lajoie-Mazenc I, Favre G, Pédelacq JD, Cabantous S.Eur J Cell Biol. 2023 Dec;102(4):151355. doi: 10.1016/j.ejcb.2023.151355. Epub 2023 Aug 21.PMID: 37639782 Free article.
Tripartite split-GFP assay to identify selective intracellular nanobody that suppresses GTPase RHOA subfamily downstream signaling.
Keller L, Tardy C, Ligat L, Le Pennec S, Bery N, Koraïchi F, Chinestra P, David M, Gence R, Favre G, Cabantous S, Olichon A.Front Immunol. 2022 Aug 18;13:980539. doi: 10.3389/fimmu.2022.980539. eCollection 2022.PMID: 36059552 Free PMC article.
Nanobody-Based Quantification of GTP-Bound RHO Conformation Reveals RHOA and RHOC Activation Independent from Their Total Expression in Breast Cancer.
Keller L, Tardy C, Ligat L, Gilhodes J, Filleron T, Bery N, Rochaix P, Aquilina A, Bdioui S, Roux T, Trinquet E, Favre G, Olichon A.Anal Chem. 2021 Apr 20;93(15):6104-6111. doi: 10.1021/acs.analchem.0c05137. Epub 2021 Apr 7.PMID: 33825439
Castillo S, Gence R, Pagan D, Koraïchi F, Bouchenot C, Pons BJ, Boëlle B, Olichon A, Lajoie-Mazenc I, Favre G, Pédelacq JD, Cabantous S.Eur J Cell Biol. 2023 Dec;102(4):151355. doi: 10.1016/j.ejcb.2023.151355. Epub 2023 Aug 21.PMID: 37639782 Free article.
Tripartite split-GFP assay to identify selective intracellular nanobody that suppresses GTPase RHOA subfamily downstream signaling.
Keller L, Tardy C, Ligat L, Le Pennec S, Bery N, Koraïchi F, Chinestra P, David M, Gence R, Favre G, Cabantous S, Olichon A.Front Immunol. 2022 Aug 18;13:980539. doi: 10.3389/fimmu.2022.980539. eCollection 2022.PMID: 36059552 Free PMC article.
Nanobody-Based Quantification of GTP-Bound RHO Conformation Reveals RHOA and RHOC Activation Independent from Their Total Expression in Breast Cancer.
Keller L, Tardy C, Ligat L, Gilhodes J, Filleron T, Bery N, Rochaix P, Aquilina A, Bdioui S, Roux T, Trinquet E, Favre G, Olichon A.Anal Chem. 2021 Apr 20;93(15):6104-6111. doi: 10.1021/acs.analchem.0c05137. Epub 2021 Apr 7.PMID: 33825439